Review reveals the intratumoral microbiome as a core component of tumor microenvironments across cancers, highlighting its potential for targeted precision oncology therapeutics.
Over the past decade, the number of microbial communities identified within tumors has increased by 400%. Notably, the intratumoral microbiome, which includes bacteria, fungi, viruses, and other microorganisms within tumor tissues, was first discovered more than a century ago. Based on the updated framework of cancer characteristics, we propose that the immune microenvironment is a fundamental and variable microbial feature in cancer. Numerous studies have demonstrated that the intratumoral microbiome constitutes a critical component of the tumor microenvironment. However, due to its low biomass, characterizing its functional mechanisms remains a significant challenge. To summarize current research on the intratumoral microbiome in oncology, we first examine its establishment, homeostasis, and heterogeneity across different cancer types, followed by a comprehensive exploration of its multifaceted roles in tumor initiation and progression. Furthermore, we discuss the critical implications of the intratumoral microbiome in cancer biomarkers, antitumor therapies, and novel microbe-based anticancer strategies. In summary, this review highlights the intratumoral microbiome as an emerging therapeutic target, offering new perspectives for deciphering the complex mechanisms of cancer.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: